Although one of the signatures of these cancer is the overexpression of the EGFR, the inhibition of EGFR as main therapy has very modest efficacy due to intrinsic or acquired resistance.8 The HDACi SAHA was already shown to potentially overcome EGFR-TKI resistance in a small panel of HPV-negative HNC cell lines.16 In this study we decided to better investigate the efficacy of SAHA alone or in combination with gefitinib in a larger and heterogeneous panel of HNC cancer cell lines and to characterise the molecular mechanisms underlying its activity. The gene discussed is EGFR; the disease is cancer.